Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

11. April 2022 07:30 ET | Quelle: Provectus Biopharmaceuticals Inc.

Provectus Biopharmaceuticals Announces Presentation of Multiple Protein Kinase Signaling Targets, including WNK1, for PV-10® Immunotherapy at American Association for Cancer Research (AACR) 2022 Annual Meeting

KNOXVILLE, TN, April 11, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that preclinical research on systemic administration of investigational cancer immunotherapy PV-10 (rose...
08. März 2017 16:05 ET | Quelle: OncoMed Pharmaceuticals, Inc.

OncoMed Pharmaceuticals Announces Fourth Quarter and Full Year 2016 Financial Results

Demcizumab and Tarextumab Randomized Phase 2 Data Expected 1H 2017 Anti-TIGIT IND Accepted; GITRL-Fc IND Expected 1H 2017 OncoMed Management to Host Conference Call/Webcast this Afternoon at 4:30...
05. Juni 2016 09:00 ET | Quelle: OncoMed Pharmaceuticals, Inc.

OncoMed Presents Phase 1b Data for First-in-Class Treatments in Ovarian, Breast and Lung Cancer at the 2016 ASCO Annual Meeting

First Presentation of Combination Data for Wnt Inhibitors, Ipafricept and Vantictumab Updated Data for Demcizumab and Tarextumab Also Presented CHICAGO and REDWOOD CITY, Calif., June 05, 2016 ...